Humacyte

Women with AV Access face clear unmet needs.
• 50% fail AVF maturation (vs. 37% in men)1
• 30% use catheter for hemodialysis (vs. 24% in men)1
• 2× higher risk of catheter dysfunction2
• 1 in 2 use infection-prone access – catheters and synthetic grafts1

Be part of the conversation advancing care for women.
VISIT our MEDICAL INFROMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: www.humacyte.com

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

REFERENCES: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

$HUMA

We’re excited to be at VAM 2026 and proud to host a hands on/SIM Lab featuring Symvess® acellular tissue engineered vessel-tyod.

During the VAM 2026 Hands on/SIM Lab, participants can practice handling and implantation techniques, perform anastomosis, and apply proper clamping and procedural methods—all supported by the Humacyte team throughout the session.

SIM Lab Location: Hynes Convention Center, Second Level, Auditorium
• Thursday, June 11: 10:15 AM – 6:15 PM
• Friday, June 12: 9:30 AM – 2:00 PM

Be sure to also stop by Booth 307 to connect with the Humacyte team and continue the conversation.

Contact Us Here: https://symvess.com/contact-us/
Learn more about Symvess here: https://bit.ly/atev_prod_huma
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
Other trademarks are property of their respective owners.
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000348

$HUMA

Join Humacyte TODAY at The Vascular Access Society of the Americas (VASA) for a scientific presentation examining the performance of Acellular Tissue Engineered Vessels (ATEV) following repeated cannulation for dialysis access.

This talk will highlight research about ATEVs—offering insight into bioengineered conduits and vascular access durability.

VASA Annual Meeting
5:16–5:23 PM
Speakers: Maisha Clancy, MA; Juan Wang, PhD

Humacyte is a trademark and property of Humacyte Global, Inc. All other trademarks are the property of their respective owners.

© 2026 Humacyte Global Inc. All Rights Reserved.

This National Women's Health Week, we are looking back at the foundation of our company.

20+ years ago, Humacyte was born from the vision of three women - scientists and pioneers who believed that regenerative medicine could redefine the future of vascular surgery. Dr. Laura Niklason, Dr. Shannon Dahl, Dr. Juliana Blum set out to solve one of medicine's most enduring challenges: providing a reliable, off-the- shelf biologic conduit that becomes the patient's own tissue.

Two decades later, the vision is a commercial reality with the launch of Symvess® acellular tissue engineered vessel-tyod for extremity vascular injury. As a female founded company, we remain dedicated to the pursuit of scientific excellence and the improvement of patient outcomes across the vascular journey.

We celebrate the women in our labs, our offices, and the operating rooms who continue to push the boundaries of what is possible in biotechnology.

Learn more at https://humacyte.com

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING,
AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.